← The patent line

Adapalene; Benzoyl Peroxide; Clindamycin Phosphate

Sold as CABTREO · given by topical

Ten years or more until it comes off patent
14.4 yr
Until anyone may copy it
Protection runs to 2040-12-28
6
Trials running now
116 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Bausch Health Us Llc
Approval holder
the only company permitted to sell it today
2040-12
Last patent expires
latest patent filed against this product
2026-10
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

Acne VulgarisAcnePhotoaging
03

Who is paying for the research

Galderma R&D
Company
20
Bausch Health Americas, Inc.
Company
3
Stiefel, a GSK Company
Company
2

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07473895Phase 22026 · 40 people · not yet recruiting
Topical 5% Spironolactone Gel Versus 0.1% Ad

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line